Miami and New York host Cerus management's investor meetings on back-to-back days.
Cerus Corporation announced that its management will participate in two upcoming investor conferences: Citi's 2026 Global Healthcare Conference in Miami on December 1, 2026, and Piper Sandler's 38th Annual Healthcare Conference in New York on December 2, 2026. At both events, Cerus will hold one-on-one meetings with investors. The company, headquartered in Concord, California, focuses on safeguarding the global blood supply with pathogen-protected blood components and technologies.
ARK and Catherine D. Wood report their Cerus (CERS) stake, with ARK Innovation ETF’s interest above 5%.
ARK Investment Management LLC and Catherine D. Wood have reported beneficial ownership of 20,508,004 shares, or 10.18% of Cerus Corp (CERS) common stock, as of September 30, 2026. This disclosure, filed via an amended SCHEDULE 13G/A, indicates that ARK Innovation ETF holds an interest exceeding 5% in Cerus. Catherine D. Wood is identified as the CEO and Chief Investment Officer.
Cerus Corporation (CERS) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial data for Cerus Corporation (CERS), including its stock price, historical performance, key metrics like market cap and EPS, and an overview of its biomedical products. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety by reducing blood-borne pathogens. The article also includes recent news, performance against benchmarks, earnings trends, analyst insights, and valuation measures.
Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
Cerus Corporation (Nasdaq: CERS) announced its management will attend the 17th Annual Craig-Hallum Alpha Select Conference in New York City on November 17, where they will host one-on-one investor meetings. The company, headquartered in Concord, California, specializes in safeguarding the world's blood supply with its INTERCEPT Blood System. Cerus develops and supplies pathogen-protected blood components to blood centers and hospitals, with systems approved for platelets and plasma globally, and red blood cell systems under regulatory review or in late-stage clinical development.
Cerus (NASDAQ:CERS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, despite mixed views from other analysts, which result in a consensus "hold" rating with an average price target of $5.25. The stock opened at $2.02, with a 52-week range of $1.42–$3.47 and a market capitalization of approximately $407 million. Institutional investors and hedge funds hold 78.37% of Cerus shares, while an insider recently sold 30,000 shares.
Cerus Corporation (NASDAQ:CERS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.13
Cerus Corporation (NASDAQ:CERS) reported its third-quarter results last week, with revenues slightly below analyst expectations but statutory earnings per share breaking even. Following the report, analysts updated their forecasts, decreasing revenue estimates but significantly reducing loss per share projections, leading to a 14% increase in the consensus price target to US$5.13. The company is expected to see accelerated revenue growth compared to its historical performance, outperforming the wider industry.
Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.
Cerus Corporation announced positive topline results from its Phase 3 RedeS trial for the INTERCEPT Blood System for Red Blood Cells, meeting its primary efficacy endpoint by demonstrating non-inferiority to conventional red blood cells in adjusted hemoglobin increment. The study also met its primary safety endpoints, showing no statistically significant difference in treatment-emergent adverse events. These results represent a significant step towards extending pathogen reduction technology to red blood cell transfusions.
Cerus Q3 2026 Earnings Call Is Live
Cerus's quarterly earnings call has commenced, where executives will discuss the latest financial results and answer questions from Wall Street analysts. This event is crucial for investors following CERS, as management commentary on future demand, margins, or capital spending can significantly influence market movements. The earnings call provides an opportunity for management to elaborate on the numbers and potentially reveal surprise news.
Cerus: Q3 Earnings Snapshot
Cerus Corp. (CERS) reported a third-quarter loss of $550,000, resulting in a per-share loss of less than 1 cent. The biomedical products company generated $57.7 million in revenue for the period and projects full-year revenue to be between $229 million and $231 million.
Cerus (CERS) files $150M mixed shelf
Cerus (NASDAQ: CERS) has filed a $150 million mixed shelf offering, which includes common stock, preferred stock, debt securities, and warrants. This financial move allows the company flexibility to raise capital in the future. The stock's current price is $2.26, reflecting a 4.24% decrease, with an overall analyst rating of "SELL."
Cerus reports positive phase 3 trial results for red blood cells
Cerus Corporation announced positive Phase 3 RedeS trial results for its INTERCEPT Red Blood Cells, demonstrating non-inferiority in adjusted hemoglobin increment compared to conventional red blood cells. The trial also evaluated safety endpoints, finding no statistically significant difference in treatment-emergent adverse events, though low titer, transient INTERCEPT-specific antibodies were detected in a small percentage of subjects without clinical impact. The INTERCEPT Blood System remains investigational in the United States, awaiting FDA review.
Cerus’ blood-safety system meets main goal in late-stage trial
Cerus Corp announced that its Intercept blood-safety technology met its primary endpoint in a late-stage trial, performing as effectively as conventional red blood cells in transfusion patients. The technology aims to reduce pathogens in donated blood, and the study found no statistically significant difference in adverse events. While Intercept-treated red blood cells are still experimental in the U.S., the company reported no clinical impact from temporary antibodies developed by a small number of patients.
Cerus And 2 Other Compelling Penny Stocks To Watch
This article highlights three compelling penny stocks: Cerus (CERS), SoundHound AI (SOUN), and Blend Labs (BLND), chosen for their potential growth despite being smaller companies. Each company's financial health, operational overview, market capitalization, and future outlook are discussed, emphasizing aspects like revenue growth, loss reduction, cash runways, and market developments. The report provides a brief analysis of why these stocks could be attractive to investors seeking opportunities beyond well-known enterprises.
Cerus Corp sets Nov 2 for Q3FY26 results release
Cerus Corporation will release its third quarter 2026 financial results on Monday, November 2, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 pm ET to discuss the results and provide a business overview. A replay of the call will be available on their website until November 23, 2026.
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
Cerus Corporation (Nasdaq: CERS) announced that it will release its third quarter 2026 financial results on Monday, November 2, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview. Interested parties can access the webcast and presentation slides via the investor relations page on the Cerus website.
A workshop will share one hospital's experience using treated platelets and a clotting product
Cerus Corporation (Nasdaq: CERS) announced it will host an industry workshop at the 2026 AABB Annual Meeting in Atlanta, Georgia, focusing on the real-world experiences with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex (IFC). The workshop will feature speakers from Grady Health System sharing their implementation and impact of these technologies. Additionally, Cerus will present various scientific data through oral and poster presentations at the meeting, highlighting advancements in transfusion medicine.
Cerus Corporation (CERS) - What Are Analysts Saying About This Stock?
Analysts have issued a consensus "Hold" rating for Cerus Corporation (CERS), with an average 12-month price target of $5.25. The company recently met earnings expectations with a loss of $0.01 per share and revenue of $63.3 million. Institutional ownership is high at 78.37%, though an insider recently sold 30,000 shares.
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Cerus Corporation (Nasdaq: CERS) announced its participation in the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17-19. The company will host an industry workshop focused on real-world experiences with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex (IFC), and will also feature several oral and poster presentations covering various aspects of its pathogen reduction technologies. Cerus aims to engage with the transfusion medicine community and share scientific data regarding its vital blood safeguarding technologies.
Cerus Corp. Stock Grades | CERS
This article provides a stock grade overview for Cerus Corp. (CERS), including its average analyst price target and score, sentiment, and key financial metrics like market value, EPS, and short interest. It also details the company's business activities in biomedical and surgical product development, specifically its INTERCEPT brand for blood systems.
CERS: Cerus Corp. Latest Stock Price, Analysis, News and Trading Ideas
The article provides the latest stock price for Cerus Corp. (CERS), showing it closed at $2.34 with a slight after-hours gain. It includes investor sentiment and trading ideas, with one investor anticipating a significant share price increase based on upcoming data related to RBC. Another investor notes consistent buyer interest in the stock.
Bank of America Corp DE Acquires 868,457 Shares of Cerus Corporation $CERS
Bank of America Corp DE recently acquired 868,457 shares of Cerus Corporation (CERS) in the second quarter, valued at approximately $2.54 million. This acquisition represents about 0.43% of Cerus, a biotechnology company focused on blood transfusion safety. Institutional investors and hedge funds now collectively own 78.37% of CERS, while analyst opinions are mixed, resulting in a consensus "Hold" rating.
Cerus Number of Employees 2026 | Employee Count & Headcount Data
Cerus Corp. (CERS) had approximately 286 employees worldwide as of March 2026, marking a 0.5% decline since 2023. The company is actively hiring, with 11 active job postings in 2026, a 93.3% increase from the previous year. Cerus's workforce is primarily concentrated in North America, with an average salary of $178,533.
Cerus (NASDAQ:CERS) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?
Cerus (NASDAQ:CERS) stock recently crossed above its 200-day moving average, trading at $2.53 with a 200-day moving average of $2.48. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $5.25. The company met its quarterly EPS expectations and reported $63.3 million in revenue, while institutional investors own a significant portion of the company and insiders have recently sold shares.
Bank of New York Mellon Corp Invests $1.64 Million in Cerus Corporation $CERS
Bank of New York Mellon Corp has acquired 559,834 shares of Cerus Corporation (NASDAQ:CERS) worth approximately $1.64 million in the second quarter, making it a new position for the institution. Cerus, a biomedical products company, reported Q2 revenues of $63.3 million and a -$0.01 EPS, aligning with analyst estimates. Despite mixed analyst sentiment and the company's unprofitability, institutional investors now own 78.37% of Cerus.
Cerus (NASDAQ:CERS) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, despite the broader analyst consensus remaining "Hold" with an average price target of $5.25. Cerus met analyst expectations with quarterly revenue of $63.3 million and an adjusted EPS of $(0.01), and analysts project a $(0.04) loss per share for the full fiscal year. The company's stock opened at $2.59, and institutional investors own 78.37% of shares, while recent insider sales were primarily for tax withholding obligations.
Cerus Corp chief legal officer sells $89,529 in company stock.
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 30,000 shares of company stock for $89,529 on August 17, 2026, as part of a pre-arranged trading plan. This sale occurred while Cerus shares were trading near $2.97, having increased significantly over the past year. Despite the insider sale, the company recently surpassed Q2 2026 financial expectations, though concerns about margin pressure and short-term cash usage persist.
Cerus (NASDAQ: CERS) insider moves to sell more stock after July sale
Chrystal Nikole Jensen, an insider at Cerus (NASDAQ: CERS), has filed a Form 144 notice to sell up to 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 17, 2026. This proposed sale follows a previous sale of 24,329 common shares on July 1, 2026, within the last three months. The filing also details prior restricted stock awards to Jensen in 2021 and 2022.
Cerus Corp chief legal officer sells $89,529 in company stock.
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 30,000 shares of company stock totaling $89,529 on August 17, 2026, as part of a pre-arranged trading plan. The sale occurred while Cerus shares were trading near $2.97, reflecting significant gains over the past year. Despite positive Q2 2026 financial results, including an earnings beat and raised revenue guidance, the company faced concerns regarding margin pressure and cash usage.
Cerus Corp chief legal officer sells $89,529 in company stock. By Investing.com
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 30,000 shares of company stock totaling $89,529 on August 17, 2026, as part of a pre-arranged trading plan. This sale occurred while Cerus shares were trading near $2.97, reflecting significant gains over the past year and week, though InvestingPro analysis suggests the stock might be slightly overvalued. The company recently reported strong Q2 2026 financial results, exceeding revenue and profit forecasts, despite concerns about margin pressure and short-term cash usage.
Cerus (CERS) legal chief sells 30,000 shares in preset plan
Cerus (CERS) Chief Legal Officer Chrystal Jensen sold 30,000 shares of common stock on August 17, 2026, as part of a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $2.9843, with individual prices ranging from $2.92 to $3.04. Following this transaction, Jensen directly holds 936,657 shares of Cerus common stock.
Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS
Assenagon Asset Management S.A. significantly reduced its stake in Cerus Corporation by 74.8% in the second quarter, selling 936,043 shares but still retaining 315,050 shares valued at approximately $920,000. Despite this reduction, institutional investors collectively own 78.37% of Cerus. The biotechnology company reported quarterly revenue of $63.3 million and adjusted EPS of $(0.01), meeting analyst expectations, with analysts projecting a full-year loss of about $0.04 per share.
Baker Bros. cuts Cerus Corporation (CERS) position to 3.2% ownership stake
Baker Bros. Advisors LP and related reporting persons have filed an Amendment No. 13 indicating a reduction in their beneficial ownership of Cerus Corporation (CERS) common stock to 3.2%. This ownership comprises 6,395,431 shares held by Baker Brothers Life Sciences, L.P. and 667, L.P., with Julian C. Baker and Felix J. Baker each individually owning an additional 19,864 shares, totaling 6,415,295 shares for each principal. The updated ownership percentage is based on 201,457,000 shares of common stock outstanding as of June 30, 2026.
Cerus Corp (CERS): ARK Investment, Catherine Wood report 8.95% ownership stake
ARK Investment Management LLC and its CEO/CIO Catherine D. Wood have reported a beneficial ownership stake of 8.95% in Cerus Corp (CERS) common stock through an amended Schedule 13G/A filing. As of June 30, 2026, they collectively own 17,932,099 shares. The filing details ARK's sole voting power over 16,642,316 shares and shared voting power over 226,246 shares, while Catherine Wood reports shared voting power over 16,868,562 shares and shared dispositive power over all 17,932,099 shares.
Cerus Corp (CERS) sees Soleus Capital group report 1.2% beneficial stake
Soleus Capital Master Fund, L.P., and its related entities, including Guy Levy, have filed an amended Schedule 13G indicating beneficial ownership of 2,500,000 shares of Cerus Corporation (CERS) common stock, which represents 1.2% of the outstanding shares. This filing confirms that the group now holds 5% or less of Cerus common stock and exercises shared voting and dispositive power over all reported shares. The shares outstanding figure of 201,524,898 is based on Cerus's Form 10-Q filing from July 16, 2026.
Wasatch Advisors LP Sells 1,897,237 Shares of Cerus Corporation $CERS
Wasatch Advisors LP reduced its stake in Cerus Corporation by 35.9% in the second quarter, selling 1,897,237 shares but still retaining 3.38 million shares valued at approximately $9.9 million. Cerus reported quarterly revenue of $63.3 million and an adjusted loss of $0.01 per share, meeting analyst expectations. The company currently holds a "Hold" consensus rating from analysts with an average price target of $4.00, while insiders have sold shares primarily to cover tax obligations.
Cerus Corp (CERS) Stock News Today
This page provides the latest news and information for Cerus Corp (CERS) stock on TradingKey, a financial information platform. As of August 7th, Cerus Corp's stock closed at $2.350, up 1.29%. The platform also offers an overview, news and analysis, financial data, stock score, technical forecast, ownership details, dividends, and profile information for CERS.
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 17th in its industry, with an average analyst price target of $5.00, suggesting a 113.09% upside. Based on 3 analysts, the stock is rated as a "Buy." The company's expected revenue for the next quarter is $61.60 million, and its EPS for the previous and next quarters is estimated at -$0.01.
Cerus Corp 2Q 2026: Revenue $57.4M, EPS $(0.01) — 10-Q Summary
Cerus Corp (CERS) reported its second-quarter 2026 results, showing revenue of $57.4 million, an increase from $52.4 million in the prior year. The company also narrowed its net loss to $(2.94) million from $(5.71) million, and its diluted loss per share improved to $(0.01) from $(0.03) year-over-year. Key highlights included a 10% rise in product revenue driven by increased disposable platelet/plasma kit and IFC sales in the U.S., progress in Phase 3 trials for the red blood cell system, and expanding global adoption of its products.
CERS Slides After Sharp Repricing Raises Trading Focus
Cerus Corporation (CERS) stock has dropped significantly by 23.88% due to adverse regulatory news and increased bearish sentiment. The company, which operates in blood safety, shows solid revenue growth but remains unprofitable, making it a high-risk, high-reward stock for traders. Analysts note its adequate liquidity but elevated leverage, suggesting a challenging path to sustainable profitability, with traders focusing on whether current price levels will form a base or lead to further decline.
Cerus (NASDAQ:CERS) Announces Earnings Results, Meets Expectations
Cerus (NASDAQ:CERS) announced its earnings results, meeting analyst expectations with a quarterly loss of $0.01 per share and revenue of $63.3 million, slightly above the $62.9 million forecast. The company reported a 10% increase in product revenue to $57.4 million, driven by significant growth in INTERCEPT fibrinogen complex revenue, and raised its 2026 product revenue guidance. Despite a decline in gross margin and negative operating cash flow, Cerus refinanced its debt and submitted its INT200 platelet application to the FDA, with potential approval in early 2027.
Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours
Cerus Corporation reported Q2 2026 results that surpassed analyst estimates for both profit and revenue, with an adjusted EPS loss of $0.01 against an expected loss of $0.03, and revenue of $63.3 million compared to a $62.9 million forecast. Despite the beat and raised full-year product revenue guidance, the company's shares dropped 15.21% in after-hours trading, likely due to investor concerns over margin pressure and negative operating cash flow. The blood-safety company highlighted strong product revenue growth, particularly from its U.S. IFC franchise, and continued progress towards GAAP profitability.
Cerus reports Q2 2026 revenue $63.3M; product revenue $57.4M, raises 2026 product guidance
Cerus reported Q2 2026 total revenue of $63.3 million and product revenue of $57.4 million, marking a 10% year-over-year increase. The company raised its full-year product revenue guidance to $229–$231 million and highlighted accelerating demand for INTERCEPT Fibrinogen Complex in the U.S. Cerus also submitted a PMA for its INT200 illuminator and completed a debt refinancing.
Cerus Corp (CERS) beats Q2 2026 revenue by 7.5% on INTERCEPT surge
Cerus Corp (CERS) exceeded its Q2 2026 revenue expectations by 7.5%, reporting $63 million against an estimated $59 million, driven by the strong performance of its INTERCEPT blood safety franchise. The company also announced a positive outlook for fibrinogen product sales, projecting 40% to 50% growth through year-end. This revenue beat continues an upward trend in quarterly sales for Cerus, while its EPS came in line with estimates at -$0.01.
Cerus Corp (CERS) Cash Flow
This article provides a detailed cash flow statement for Cerus Corp (CERS), offering both quarterly and annual data for operating, investing, and financing activities over several fiscal years. It breaks down key components such as net income, changes in working capital, capital expenditures, and debt/equity transactions. Additionally, it includes FAQs explaining various cash flow metrics and their relevance for investors.
CERS|Cerus Corp|Price:3.045|Chg%:-0.025
This article provides a comprehensive stock analysis of Cerus Corp (CERS) from TradingKey, highlighting its "relatively healthy" fundamentals and high growth potential. The company's valuation is deemed "fairly valued," ranking it 45 out of 199 in its industry, with high institutional ownership and a "Buy" rating from multiple analysts, who suggest a target price of 4.50. The article details Cerus Corp's business as a biomedical products company focused on blood safety, utilizing its INTERCEPT Blood System, and breaks down Cerus's score across various financial and market dimensions.
Cerus Corp (CERS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Cerus Corp (CERS), detailing its income sources by business segment and geographical region. As of the stated update, Product sales account for 88.17% of revenue, with Government Contracts making up 11.83%. Geographically, the United States contributes the majority at 65.18%, followed by Other Countries and France.
Cerus Corp (CERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Cerus Corp (CERS). It shows that the company has not distributed any dividends over the past five years. The page displays current stock metrics, including share price and market capitalization, but no historical payout data is available.
Cerus Corp (CERS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cerus Corp (CERS), listing its major shareholders and their respective holdings, alongside an overview of institutional holdings and their changes over recent quarters. Key individual institutional holders include ARK Investment Management LLC, BlackRock Institutional Trust Company, N.A., and Baker Bros. Advisors LP. The article also categorizes shareholders by type and notes related ETF holdings.
TradingKey
This article provides a detailed quarterly and annual income statement for Cerus Corp (CERS) from FY2012Q1 to FY2026Q1, highlighting key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret Cerus Corp's financial data on TradingKey, emphasizing the importance of analyzing various metrics to understand the company's performance, growth, and profitability.
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cerus Corp (CERS), highlighting its current earnings forecast score of 8.67, ranking 18th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $5.00 for CERS, with most recommending a "Buy." The report also includes expected revenue and EPS for upcoming quarters.